The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: The VA Cooperative Study in diabetes

M. Sue Kirkman, Madeline McCarren, Jayendra Shah, William Duckworth, Carlos Abraira

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The problem: Macrovascular disease (MVD), especially coronary heart disease, is the most common cause of mortality in Type 2 diabetes. We assessed the association between demographic and clinical variables (particularly HbA1c) and prevalent MVD at time of enrollment into the VA Diabetes Trial (VADT), a 7-year randomized trial to determine whether intensive glycemic control will reduce risk of MVD events in older participants with established Type 2 diabetes. Research design and methods: We compared the demographic, treatment, and clinical characteristics of participants with and without known MVD, then assessed the interaction of multiple variables with HbA1c. Logistic regression models evaluated the association between HbA1c quartiles and prevalence of MVD, adjusting for potentially confounding variables. Results: Several variables were associated with prevalent MVD (age, duration of diabetes, insulin use but not daily dosage, smoking history, hypertension, BMI, Caucasian race, non-Hispanic ethnicity, lower HDL cholesterol, higher triglycerides, lower LDL cholesterol, and statin use). In univariate analysis, there was no association of HbA1c with MVD (mean: 9.4±1.46% in those with MVD, 9.5±1.58% in those without). Multivariate analyses found little confounding of the lack of association of HbA1c with MVD. Only adjustment for age produced a slight increase in the odds ratio, but only for the highest quartile of HbA1c. Conclusions: In this cross-sectional analysis, MVD was associated with a number of clinical and demographic variables but not with HbA1c. Determining whether intensive lowering of HbA1c will reduce the prospective rate of MVD events in this population of older participants with established Type 2 diabetes is the primary objective of our trial.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalJournal of Diabetes and its Complications
Volume20
Issue number2
DOIs
StatePublished - Mar 1 2006

Fingerprint

Type 2 Diabetes Mellitus
Demography
Logistic Models
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Confounding Factors (Epidemiology)
LDL Cholesterol
HDL Cholesterol
Coronary Disease
Triglycerides
Research Design
Multivariate Analysis
Cross-Sectional Studies
Smoking
History
Odds Ratio
Insulin
Hypertension
Mortality

Keywords

  • Glycemic control
  • Macrovascular disease

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes : The VA Cooperative Study in diabetes. / Kirkman, M. Sue; McCarren, Madeline; Shah, Jayendra; Duckworth, William; Abraira, Carlos.

In: Journal of Diabetes and its Complications, Vol. 20, No. 2, 01.03.2006, p. 75-80.

Research output: Contribution to journalArticle

Kirkman, M. Sue ; McCarren, Madeline ; Shah, Jayendra ; Duckworth, William ; Abraira, Carlos. / The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes : The VA Cooperative Study in diabetes. In: Journal of Diabetes and its Complications. 2006 ; Vol. 20, No. 2. pp. 75-80.
@article{ec6dbf2932d4440293aab47d25d4d891,
title = "The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: The VA Cooperative Study in diabetes",
abstract = "The problem: Macrovascular disease (MVD), especially coronary heart disease, is the most common cause of mortality in Type 2 diabetes. We assessed the association between demographic and clinical variables (particularly HbA1c) and prevalent MVD at time of enrollment into the VA Diabetes Trial (VADT), a 7-year randomized trial to determine whether intensive glycemic control will reduce risk of MVD events in older participants with established Type 2 diabetes. Research design and methods: We compared the demographic, treatment, and clinical characteristics of participants with and without known MVD, then assessed the interaction of multiple variables with HbA1c. Logistic regression models evaluated the association between HbA1c quartiles and prevalence of MVD, adjusting for potentially confounding variables. Results: Several variables were associated with prevalent MVD (age, duration of diabetes, insulin use but not daily dosage, smoking history, hypertension, BMI, Caucasian race, non-Hispanic ethnicity, lower HDL cholesterol, higher triglycerides, lower LDL cholesterol, and statin use). In univariate analysis, there was no association of HbA1c with MVD (mean: 9.4±1.46{\%} in those with MVD, 9.5±1.58{\%} in those without). Multivariate analyses found little confounding of the lack of association of HbA1c with MVD. Only adjustment for age produced a slight increase in the odds ratio, but only for the highest quartile of HbA1c. Conclusions: In this cross-sectional analysis, MVD was associated with a number of clinical and demographic variables but not with HbA1c. Determining whether intensive lowering of HbA1c will reduce the prospective rate of MVD events in this population of older participants with established Type 2 diabetes is the primary objective of our trial.",
keywords = "Glycemic control, Macrovascular disease",
author = "Kirkman, {M. Sue} and Madeline McCarren and Jayendra Shah and William Duckworth and Carlos Abraira",
year = "2006",
month = "3",
day = "1",
doi = "10.1016/j.jdiacomp.2005.06.013",
language = "English",
volume = "20",
pages = "75--80",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes

T2 - The VA Cooperative Study in diabetes

AU - Kirkman, M. Sue

AU - McCarren, Madeline

AU - Shah, Jayendra

AU - Duckworth, William

AU - Abraira, Carlos

PY - 2006/3/1

Y1 - 2006/3/1

N2 - The problem: Macrovascular disease (MVD), especially coronary heart disease, is the most common cause of mortality in Type 2 diabetes. We assessed the association between demographic and clinical variables (particularly HbA1c) and prevalent MVD at time of enrollment into the VA Diabetes Trial (VADT), a 7-year randomized trial to determine whether intensive glycemic control will reduce risk of MVD events in older participants with established Type 2 diabetes. Research design and methods: We compared the demographic, treatment, and clinical characteristics of participants with and without known MVD, then assessed the interaction of multiple variables with HbA1c. Logistic regression models evaluated the association between HbA1c quartiles and prevalence of MVD, adjusting for potentially confounding variables. Results: Several variables were associated with prevalent MVD (age, duration of diabetes, insulin use but not daily dosage, smoking history, hypertension, BMI, Caucasian race, non-Hispanic ethnicity, lower HDL cholesterol, higher triglycerides, lower LDL cholesterol, and statin use). In univariate analysis, there was no association of HbA1c with MVD (mean: 9.4±1.46% in those with MVD, 9.5±1.58% in those without). Multivariate analyses found little confounding of the lack of association of HbA1c with MVD. Only adjustment for age produced a slight increase in the odds ratio, but only for the highest quartile of HbA1c. Conclusions: In this cross-sectional analysis, MVD was associated with a number of clinical and demographic variables but not with HbA1c. Determining whether intensive lowering of HbA1c will reduce the prospective rate of MVD events in this population of older participants with established Type 2 diabetes is the primary objective of our trial.

AB - The problem: Macrovascular disease (MVD), especially coronary heart disease, is the most common cause of mortality in Type 2 diabetes. We assessed the association between demographic and clinical variables (particularly HbA1c) and prevalent MVD at time of enrollment into the VA Diabetes Trial (VADT), a 7-year randomized trial to determine whether intensive glycemic control will reduce risk of MVD events in older participants with established Type 2 diabetes. Research design and methods: We compared the demographic, treatment, and clinical characteristics of participants with and without known MVD, then assessed the interaction of multiple variables with HbA1c. Logistic regression models evaluated the association between HbA1c quartiles and prevalence of MVD, adjusting for potentially confounding variables. Results: Several variables were associated with prevalent MVD (age, duration of diabetes, insulin use but not daily dosage, smoking history, hypertension, BMI, Caucasian race, non-Hispanic ethnicity, lower HDL cholesterol, higher triglycerides, lower LDL cholesterol, and statin use). In univariate analysis, there was no association of HbA1c with MVD (mean: 9.4±1.46% in those with MVD, 9.5±1.58% in those without). Multivariate analyses found little confounding of the lack of association of HbA1c with MVD. Only adjustment for age produced a slight increase in the odds ratio, but only for the highest quartile of HbA1c. Conclusions: In this cross-sectional analysis, MVD was associated with a number of clinical and demographic variables but not with HbA1c. Determining whether intensive lowering of HbA1c will reduce the prospective rate of MVD events in this population of older participants with established Type 2 diabetes is the primary objective of our trial.

KW - Glycemic control

KW - Macrovascular disease

UR - http://www.scopus.com/inward/record.url?scp=33644558032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644558032&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2005.06.013

DO - 10.1016/j.jdiacomp.2005.06.013

M3 - Article

C2 - 16504835

AN - SCOPUS:33644558032

VL - 20

SP - 75

EP - 80

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 2

ER -